Abstract
Notwithstanding the significant impact of highly active antiretroviral therapy (HAART) on human immunodeficiency virus (HIV)-associated morbidity and mortality, HAART-induced immune restitution is not complete. The potential utility of interleukin (IL)-2 to augment immune function has been extensively evaluated. Intravenous or subcutaneous IL-2 has been conclusively shown to induce significant increases in CD4 cell counts in HIV-infected patients, in particular when given concomitantly with HAART. Large randomized clinical trials are underway to investigate whether these CD4 cell increments will result in tangible clinical benefits.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 791-801 |
| Number of pages | 11 |
| Journal | Drugs of Today |
| Volume | 42 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2006 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)